Lite Strategy, INC. (LITS) — 10-Q Filings

All 10-Q filings from Lite Strategy, INC.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (6)

Lite Strategy Pivots to Litecoin, Cuts Losses Amidst Treasury Shift — Nov 14, 2025 Risk: high
Lite Strategy, Inc. (LITS) reported a net loss of $3.639 million for the three months ended September 30, 2025, a significant improvement from the $8.007 millio
MEI Pharma Files Q3 2025 10-Q, Details Revenue and Agreements — May 13, 2025 Risk: medium
MEI Pharma, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported revenue from collaboration agreements and contract with customers. Ke
MEI Pharma Files Q2 2025 10-Q — Feb 12, 2025 Risk: medium
MEI Pharma, Inc. filed its 10-Q for the period ending December 31, 2024, reporting on its financial performance for the second quarter. The company's fiscal yea
MEI Pharma Q1 2025 Update: Focus on Operations — Nov 12, 2024 Risk: medium
MEI Pharma, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported revenue from collaboration agreements for the three months ended
MEI Pharma, Inc. Files 10-Q for Period Ending March 31, 2024 — May 9, 2024 Risk: medium
MEI Pharma, Inc. (LITS) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. MEI Pharma, Inc. filed a 10-Q report for the quarter ended March 31, 2024.
MEI Pharma, Inc. Files 10-Q for Period Ending December 31, 2023 — Feb 13, 2024 Risk: medium
MEI Pharma, Inc. (LITS) filed a Quarterly Report (10-Q) with the SEC on February 13, 2024. MEI Pharma, Inc. filed a 10-Q report for the period ending December 3

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX